Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Eagle Asset Management Inc.

Eagle Asset Management Inc. lowered its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 17.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 294,280 shares of the company’s stock after selling 63,353 shares during the quarter. Eagle Asset Management Inc.’s holdings in Protagonist Therapeutics were worth $13,605,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Farallon Capital Management LLC boosted its position in shares of Protagonist Therapeutics by 1.8% during the 2nd quarter. Farallon Capital Management LLC now owns 5,840,773 shares of the company’s stock worth $202,383,000 after purchasing an additional 101,800 shares during the period. Vanguard Group Inc. lifted its stake in Protagonist Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after purchasing an additional 39,055 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of Protagonist Therapeutics by 405,061.2% during the third quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company’s stock worth $78,034,000 after buying an additional 1,733,662 shares during the period. Perceptive Advisors LLC grew its stake in shares of Protagonist Therapeutics by 27.6% in the second quarter. Perceptive Advisors LLC now owns 1,268,735 shares of the company’s stock valued at $43,962,000 after buying an additional 274,412 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Protagonist Therapeutics by 2,135.6% in the 2nd quarter. Millennium Management LLC now owns 958,283 shares of the company’s stock valued at $33,205,000 after buying an additional 915,418 shares during the period. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Insider Activity at Protagonist Therapeutics

In other news, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the transaction, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $540,000. This represents a 40.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Arturo Md Molina sold 1,906 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $40.98, for a total value of $78,107.88. Following the sale, the insider now directly owns 46,444 shares in the company, valued at $1,903,275.12. This trade represents a 3.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,109 shares of company stock valued at $1,069,999 over the last quarter. 5.40% of the stock is owned by insiders.

Protagonist Therapeutics Trading Up 11.5 %

Shares of NASDAQ:PTGX opened at $46.46 on Friday. The company has a market cap of $2.77 billion, a PE ratio of 17.47 and a beta of 2.17. The company’s 50 day moving average is $45.25 and its two-hundred day moving average is $39.16. Protagonist Therapeutics, Inc. has a 52 week low of $16.80 and a 52 week high of $48.89.

Wall Street Analysts Forecast Growth

PTGX has been the subject of a number of research analyst reports. TD Cowen upgraded Protagonist Therapeutics to a “strong-buy” rating in a report on Wednesday, September 25th. JMP Securities lowered their price objective on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. Wedbush reissued an “outperform” rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. Finally, StockNews.com raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Protagonist Therapeutics currently has an average rating of “Buy” and a consensus target price of $53.57.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.